Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Seres Therapeutics ( (MCRB) ) just unveiled an update.
Seres Therapeutics announced the completion of the VOWST asset sale in September 2024, which provided significant financial resources to advance their SER-155 development program. This strategic move has extended their operational runway into early 2026, enabling the company to focus on expanding their pipeline and reducing cash burn. The company aims to leverage these resources to pursue strategic partnerships and broaden the therapeutic potential of SER-155, which has shown promise in treating conditions like allo-HSCT and other immune-related diseases.
More about Seres Therapeutics
Seres Therapeutics is a biotechnology company focused on developing biotherapeutics based on the human microbiome. Their primary products include microbiome therapeutics such as VOWST, which was the first oral microbiome therapeutic approved by the FDA. The company targets various health issues, including infections and immune diseases, with a significant focus on conditions related to the gastrointestinal microbiome.
YTD Price Performance: 0.12%
Average Trading Volume: 2,507,723
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $144.2M
For a thorough assessment of MCRB stock, go to TipRanks’ Stock Analysis page.
